Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.
GlaxoSmithKline Protocol Summaries: Firategrast
Testosterone treatment in multiple sclerosis: a pilot study.
Teriflunomide modest help but safe for MS
Experimental models of spontaneous autoimmune disease in the central nervous system.
Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
MHC transmission: insights into gender bias in MS susceptibility.
The neuroendocrine axis in patients with multiple sclerosis.
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Pregnancy and multiple sclerosis.
Biogen Idec reports positive top-line results from Phase 2 anti-LINGO-1 trial in people with acute optic neuritis
US patent office grants patent claiming dosing regimen for TECFIDERA™ (dimethyl fumarate)
Sex differences in autoimmune disease.
17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Best practice in the use of natalizumab in multiple sclerosis.
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.

Pages